Management of secondary hyperparathyroidism: how and why? - Wikidata - awgldk - TriplyDB

Management of secondary hyperparathyroidism: how and why?

Management of secondary hyperparathyroidism: how and why?

http://www.wikidata.org/entity/Q38775426

about

Thyrotoxicosis Occurring in Secondary Hyperparathyroidism Patients Undergoing Dialysis after Total Parathyroidectomy with Autotransplantation An introduction to CKD-MBD research: restart for the future.Therapeutic experience of severe and recurrent secondary hyperparathyroidism in a patient on hemodialysis for 18 years: A case report.

P2860

Q41377302-8E889E3A-632D-48E8-8A27-074B4CA63B5F Q48063902-615DC2AD-6175-4D2B-8B6A-0315907FCEF2 Q54936202-6F8F9245-CBD9-4C21-B004-3AEE9242AD53

P2860

Management of secondary hyperparathyroidism: how and why?

http://www.wikidata.org/entity/Q38775426

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Management of secondary hyperparathyroidism: how and why?

@en

type

label

Management of secondary hyperparathyroidism: how and why?

@en

prefLabel

Management of secondary hyperparathyroidism: how and why?

@en

P1433

Q38775426-B8C5B771-F78C-4352-B31F-511526EAD226

P1476

Q38775426-3E41E486-536A-4119-A93D-D8C27A6AA265

P2093

Q38775426-93F32B6F-F84D-4DE0-BBB8-248CB8AB18D6

P2860

Q38775426-005184B4-12EB-4BEC-B6DC-B93E00C6FDD7

Q38775426-092AAC48-56B7-42E1-8B8A-16EDFB259039

Q38775426-1092DB07-E1F2-49E5-AD45-1BDA09C17691

Q38775426-194000CF-97B0-40E9-A7BB-4A5FE09C601F

Q38775426-1A414CAD-9E25-4D09-82F9-73376E5F95A9

Q38775426-1EB70387-86C1-40B7-8C6F-47F0D11A39CA

Q38775426-1EC05F2C-9E60-4811-8C9F-0C9BDAF85052

Q38775426-23194274-CF83-4C67-8DED-7B858BC9C612

Q38775426-23973A75-5DFD-4D70-907E-3FA53C6B11ED

Q38775426-280A43CA-F2EC-421E-AB30-4F37232B2D16

P2888

Q38775426-6246904B-E89C-4A5F-916C-CFB50CB9881F

P304

Q38775426-1CB6EA7D-68DD-4B10-8306-548A348CD84A

P31

Q38775426-88BD1C69-265C-4223-805B-7D3EF12DAE8D

P356

Q38775426-C0D44FD1-53CA-42A2-982C-08A2C8943A14

P433

Q38775426-85D48DF5-753C-4B64-81B8-FA5BA138AAF8

P478

Q38775426-8D10A0B3-5CC8-4F1F-9C56-3A4DCA869560

P50

Q38775426-1D4F1DCF-B0F7-4635-A241-48839F30677C

Q38775426-6391C47B-3FD3-4492-BE57-B2FBDBD62392

P577

Q38775426-2E914436-062F-4CF2-B00C-DAAACB70CEC3

P698

Q38775426-A5970E40-08C7-4E9A-A6CC-C87920EAC307

P921

Q38775426-915BB737-DAA6-45B2-B0D9-B90DF56D6B56

P356

S10157-016-1369-2

P1433

Clinical and experimental nephrology

P1476

Management of secondary hyperparathyroidism: how and why?

@en

P2093

Takatoshi Kakuta

http://www.w3.org/2001/XMLSchema#string

P2860

FGF23 signaling impairs neutrophil recruitment and host defense during CKD.

PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop

Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease

Hyperphosphatemia is a combined function of high serum PTH and high dietary protein intake in dialysis patients.

FGF23 induces left ventricular hypertrophy

Effects of parathyroid hormone on immune function.

Uric acid levels, kidney function, and cardiovascular mortality in US adults: National Health and Nutrition Examination Survey (NHANES) 1988-1994 and 1999-2002

Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism.

Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients.

Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study.

P2888

s10157-016-1369-2

P304

37-45

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10157-016-1369-2

http://www.w3.org/2001/XMLSchema#string

P433

Suppl 1

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

Hirotaka Komaba

Masafumi Fukagawa

P577

2017-01-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28044233

http://www.w3.org/2001/XMLSchema#string

P921

hyperparathyroidism